

## FARMACOSMO: THE SHAREHOLDERS' MEETING APPROVES THE 2021 FINANCIAL STATEMENTS, THE ALLOCATION OF THE PROFIT FOR THE YEAR AND THE DISTRIBUTION OF A DIVIDEND OF EURO 0.01 PER SHARE

Milan, 29 April 2022

The Shareholders' Meeting of **Farmacosmo S.p.A.** ('Company', 'Farmacosmo', ticker: COSMO), a company active in the Health, Pharma & Beauty sectors, met today in ordinary session and passed the following resolutions.

### FINANCIAL STATEMENTS AS OF THE 31ST OF DECEMBER 2021

The Shareholders' Meeting examined and approved the annual financial statements as of the 31st of December 2021. Below are the main results that have been achieved by the Company:

- **Revenues** that amount to € 58.0 million, **+32%** compared to € 44.1 million in the previous year. The trend of growth of Farmacosmo, which recorded a **CAGR of around 54%** over the period **2016-2021**;
- **Value of Production** amounted to € 58.5 million, **+32%** compared to the financial year 2020 (€ 44.5 million);
- **EBITDA amounted to** € 1.5 million, **+36%** compared to € 1.1 million in the previous year. The profitability of the innovative circular model of the *l(ea)n strategy* is confirmed;
- **EBIT** amounted to € 1.1 million, **+15%** compared to the financial year 2020 (€ 0.9 million) after depreciation and amortisation of € 424 thousand, mainly due to research and development projects;
- **Net Profit** amounted to € 413 thousand, **+11%** compared to € 373 thousand as at 31 December 2020;
- The **Net Financial Position** is '**cash positive**' in the amount of € 839 thousand (*cash positive* in the amount of € 1,975 thousand in the year 2020), with cash and cash equivalents at year-end exceeding € 1.4 million;
- **Shareholders' Equity** amounted to € 967 thousand, up from € 553 thousand in the financial statements as of the 31st of December 2020;

### ALLOCATION OF PROFIT FOR THE YEAR AND DISTRIBUTION OF DIVIDENDS

With reference to the allocation of the profit for the year, which amounted to € 413,258, the Shareholders' Meeting resolved to:

- Allocate € 20,662.90 to the legal reserve;
- Allocate € 17,040.10 to retained earnings;
- To distribute dividends in the amount of € 375,555, awarding a gross unit dividend of € 0.01 per share, in a lump sum, with the ex-dividend date on the 9th of May 2022, record date on the 10th of May 2022 and payment date from 11 May 2022.

### DOCUMENTATION

The minutes of the Shareholders' Meeting, the list of names of the participants and the summary report of the voting will be made available to the public within the terms provided for by the regulations in force at the registered office and Borsa Italiana S.p.A., as well as on the Company's website [www.farmacosmoinvestors.com](http://www.farmacosmoinvestors.com), in the section '*Investors/Shareholders' Meetings*'. The Annual Financial Report is available on the website [www.farmacosmoinvestors.com](http://www.farmacosmoinvestors.com), in the section "*Investors/Financial Statements and Reports*".

\*\*\*

This press release is available at [www.farmacosmoinvestors.com](http://www.farmacosmoinvestors.com), in the '*Investors/Press Releases*' section, and on the authorised 'eMarket Storage' mechanism ([www.emarketstorage.com](http://www.emarketstorage.com)).

\*\*\*

# FARMACOSMO+

## PRESS RELEASE

### THE SOCIETY

Farmacosmo is a company active in the *Health, Pharma & Beauty* sectors. The company's business model is based on the circular model of the I(ea)n strategy and is divided into three main business areas: *Logistics, Intelligence* and *Node*. *Logistics*: enables the management and fulfilment of up to 12,000 orders per day, with delivery times of up to 20 hours from carrier picking and just-in-time procurement ('*zero warehouse*' policy). *Intelligence*: includes strategy definition, competitive positioning and *customer journey* activities, which enabled the company to intercept c. 188,000 customers in 2021. Recurring customers contributed 74% of the annual *retail stream* turnover. The average cart value of active customers in the *retail stream* amounted to €92 (€109 related to recurring customers). *Node*: R&D activities, process innovation and IT infrastructure of the company. Over the past five years, Farmacosmo's sales value has grown by 54% (CAGR 2016-2021) and will be around €58 million in 2021. The Farmacosmo ecosystem aims to pursue standards of excellence in every part of its *value chain*, being inspired by compliance with ESG principles at all stages of the logistics process (from the packaging used for online orders to *carbon compensation* initiatives) and in the valorisation of its employees, the company's strategic asset. Farmacosmo's commitment to ESG is also underlined by the publication of its Sustainability Report 2021.

### IDENTIFICATION CODES

Ordinary Shares: ISIN IT0005487670 (Ticker COSMO)

Warrant Farmacosmo 2022-2025: ISIN IT0005487415 (Ticker WCOSMO)

### FOR FURTHER INFORMATION:

#### INVESTOR RELATIONS MANAGER

**Farmacosmo**

Via Crispi, 51 - 80121 Naples

Tel. +39 02 50042143

Fabio de Concilio [ir@farmacosmo.it](mailto:ir@farmacosmo.it)

#### EURONEXT GROWTH ADVISOR

**illimity Bank**

Via Soperga, 9 - 20124 Milan

Tel. +39 02 82849699

[farmacosmo@illimity.com](mailto:farmacosmo@illimity.com)

#### INVESTOR & MEDIA RELATIONS ADVISOR

**IR Top Consulting**

Via Bigli, 19 - 20121 Milan

Tel. +39 02 45473883

Pietro Autelitano [ir@irtop.com](mailto:ir@irtop.com)

Domenico Gentile [ufficiostampa@irtop.com](mailto:ufficiostampa@irtop.com)